The JPMorgan Healthcare Conference is the biggest health care investing event of the year. About 9,000 attendees walking in and out of meeting rooms here at the St. Francis — Westin in San Francisco. This is where attendees (investors) figure out where they’re going to put their money in the year.
Maria Bartiromo sat down exclusively with the CEO of Celgene, Bob Hugin; Bill Marth of Teva Pharmaceutical’s North America Division; the bosses at Boston Scientific, Mike Mahoney and Hank Kucheman; George Scangos at Biogen; and Jeff Leiden of Vertex. Here are the headlines.
Teva’s Bill Marth is excited about the possibility of 40 product launches this year. Marth said that’s worth “about $30 billion.”
This has been the “largest year for patent expiration in generic markets,” added Marth.
Teva is not only a powerhouse in the U.S., they “do generics around the world.”
Teva is the biggest generic drug-maker in the world. “We are number one in Europe, number three in Japan, we have growth globally. U.S. market is a great market, but the global market is a $130 billion market,” said Marth.
CelgenePage 1 of 3 | Next Page